Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet
05:35pm, Friday, 30'th May 2025
Major U.S. equities indexes were mixed in the final session of the holiday-shortened trading week as President Donald Trump reverted to an antagonistic tone on trade with China and the latest Personal
Regeneron dashes Wall Street's hopes as COPD treatment trial suffers a failure
03:19pm, Friday, 30'th May 2025
Regeneron's stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.
Itepekimab Failure A Setback For Sanofi And Regeneron
02:10pm, Friday, 30'th May 2025
Itepekimab's inconsistent phase 3 results represent a setback for Regeneron Pharmaceuticals and Sanofi. The results do not support regulatory submissions and a 3-4 year approval delay, and lower peak
Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More
12:30pm, Friday, 30'th May 2025
U.S. equities were lower at midday as the market focused on the future of U.S.-China trade. The Dow Jones Industrial Average, S&P 500, and Nasdaq all lost ground.
Regeneron shares plunge after mixed COPD drug trial results
12:05pm, Friday, 30'th May 2025
Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) sank nearly 19% on Friday after the company's experimental COPD drug, developed with partner Sanofi SA (ADR) (NYSE:SNY), posted mixed results in t
Regeneron stock crashes on COPD data: here's why I'm buying REGN today
12:04pm, Friday, 30'th May 2025
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) crashed more than 15% this morning on disappointing data from Phase 3 trials of its experimental drug itepekimab. Itepekimab is a drug candidate for chroni
Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
11:21am, Friday, 30'th May 2025
Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.
Elastic, Gap, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session
09:10am, Friday, 30'th May 2025
U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Friday.
Regeneron shares slide on mixed trial data on smoker's lung drug
06:37am, Friday, 30'th May 2025
Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of lung condition commonly called "smoker's lung" failed a late-stage trial, although it
Sanofi, Regeneron's Itepekimab Delivers Mixed Results in Late-Stage Trials
03:19am, Friday, 30'th May 2025
Sanofi and Regeneron said that drug candidate Itepekimab didn't meet primary endpoint in a phase three study, although a benefit was seen earlier in the trial.
The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move.
05:30am, Thursday, 29'th May 2025
Earlier this year, biotech company 23andMe filed for bankruptcy. The harsh reality was that its business, while enticing to people who wanted to learn about their backgrounds via DNA testing kits, was
Mary Kay Inc. Awards 10 Grants to Young Innovators at 2025 Regeneron International Science and Engineering Fair
04:29pm, Wednesday, 28'th May 2025
DALLAS--(BUSINESS WIRE)-- #MaryKay--Mary Kay Inc., a global advocate for furthering young women's education and encouraging youth to follow their STEM dreams, returned for a second year as a Special A
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis
09:00am, Wednesday, 28'th May 2025
SAN DIEGO--(BUSINESS WIRE)--Telesis Bio Inc. (OTCMKTS: TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundr
Does the 23andMe Acquisition Make Regeneron a Buy Now?
05:31am, Saturday, 24'th May 2025
Have you ever wondered if an established drugmaker could do better at genetics-guided research than a consumer-focused diagnostics business? Well, we could find out.
Regeneron Initial Data on Multiple Myeloma Drug Encouraging
05:11pm, Friday, 23'rd May 2025
REGN posts strong early data for linvoseltamab combos in relapsed/refractory multiple myeloma, with ORRs up to 90% and high complete response rates.
